While cHL demonstrates remarkable responsiveness to checkpoint inhibition, owing primarily to its characteristic amplification of PD-L1 and PD-L2, other malignancies such as NHL, AML, and MM exhibit more heterogeneous and often limited responses. This evidence concerns the gene CD274 and acute myeloid leukemia.